Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

A randomized trial of rosuvastatin in the prevention of venous thromboembolism.

Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM.

N Engl J Med. 2009 Apr 30;360(18):1851-61. doi: 10.1056/NEJMoa0900241. Epub 2009 Mar 29.

2.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group.

N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.

3.

Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.

Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM.

Ann Intern Med. 2010 Apr 20;152(8):488-96, W174. doi: 10.7326/0003-4819-152-8-201004200-00005.

4.

Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.

Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ.

Lancet. 2012 Aug 11;380(9841):565-71. doi: 10.1016/S0140-6736(12)61190-8.

6.
7.

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group.

Lancet. 2009 Apr 4;373(9670):1175-82. doi: 10.1016/S0140-6736(09)60447-5. Epub 2009 Mar 28.

PMID:
19329177
8.

The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial.

Novack V, MacFadyen J, Malhotra A, Almog Y, Glynn RJ, Ridker PM.

CMAJ. 2012 Apr 17;184(7):E367-72. doi: 10.1503/cmaj.111017. Epub 2012 Mar 19.

9.

Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).

Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group.

Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):616-23. doi: 10.1161/CIRCOUTCOMES.109.848473. Epub 2009 Sep 22.

10.

Statins for primary prevention of venous thromboembolism.

Li L, Zhang P, Tian JH, Yang K.

Cochrane Database Syst Rev. 2014 Dec 18;(12):CD008203. doi: 10.1002/14651858.CD008203.pub3. Review.

PMID:
25518837
11.

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group.

N Engl J Med. 2009 Apr 2;360(14):1395-407. doi: 10.1056/NEJMoa0810177. Epub 2009 Mar 30. Erratum in: N Engl J Med. 2010 Apr 15;362(15):1450.

12.

Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.

Ridker PM, MacFadyen JG, Glynn RJ, Chasman DI.

Circ Cardiovasc Genet. 2011 Jun;4(3):312-7. doi: 10.1161/CIRCGENETICS.110.959353. Epub 2011 Apr 14.

13.

Effect of two intensive statin regimens on progression of coronary disease.

Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE.

N Engl J Med. 2011 Dec 1;365(22):2078-87. doi: 10.1056/NEJMoa1110874. Epub 2011 Nov 15.

14.

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.

Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, Mora S, MacFadyen JG, Glynn RJ, Kastelein JJ; JUPITER Trial Study Group.

Lancet. 2010 Jul 31;376(9738):333-9. doi: 10.1016/S0140-6736(10)60713-1. Epub 2010 Jul 23.

PMID:
20655105
15.

Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.

McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J; CORONA Study Group.

Circulation. 2009 Dec 1;120(22):2188-96. doi: 10.1161/CIRCULATIONAHA.109.849117. Epub 2009 Nov 16. Erratum in: Circulation. 2010 Jun 29;121(25):e461.

17.

Rosuvastatin in older patients with systolic heart failure.

Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group.

N Engl J Med. 2007 Nov 29;357(22):2248-61. Epub 2007 Nov 5.

18.
19.

High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy.

Mora S, Glynn RJ, Ridker PM.

Circulation. 2013 Sep 10;128(11):1189-97. doi: 10.1161/CIRCULATIONAHA.113.002671. Epub 2013 Sep 3.

20.

Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean?

Shishehbor MH, Hazen SL.

Cleve Clin J Med. 2009 Jan;76(1):37-44. doi: 10.3949/ccjm.75a.08105.

Supplemental Content

Support Center